NCT04620148View on ClinicalTrials.gov

TAK-242 in Patients With Acute Alcoholic Hepatitis

PHASE2UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 31, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Acute-On-Chronic Liver Failure
Interventions
DRUG

TAK-242

TAK-242 concentrate solution 80 mg/mL for dilution and infusion

DRUG

Placebo

Matching placebo concentrate solution

Sponsors
All Listed Sponsors
collaborator

Iqvia Pty Ltd

INDUSTRY

lead

Akaza Bioscience Ltd

INDUSTRY